2017
DOI: 10.1016/j.bmc.2017.03.029
|View full text |Cite
|
Sign up to set email alerts
|

Comparative assessment of a 99m Tc labeled H1299.2-HYNIC peptide bearing two different co-ligands for tumor-targeted imaging

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
1

Year Published

2017
2017
2021
2021

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 33 publications
0
5
1
Order By: Relevance
“…[10] In the present study, we attached HYNIC as bifunctional chelator to the N-terminal of the peptide J18 for radiolabeling with 99m Tc. This result is in contrast to previous studies [11,22] where high hydrophilicity and low protein binding were achieved using EEDA/tricine as coligands. [12,13] It has been noted that some properties of the 99m Tc-labeled peptide, such as lipophilicity, stability, and protein-binding potential, are affected by the nature of the coligand.…”
Section: Discussioncontrasting
confidence: 97%
See 4 more Smart Citations
“…[10] In the present study, we attached HYNIC as bifunctional chelator to the N-terminal of the peptide J18 for radiolabeling with 99m Tc. This result is in contrast to previous studies [11,22] where high hydrophilicity and low protein binding were achieved using EEDA/tricine as coligands. [12,13] It has been noted that some properties of the 99m Tc-labeled peptide, such as lipophilicity, stability, and protein-binding potential, are affected by the nature of the coligand.…”
Section: Discussioncontrasting
confidence: 97%
“…Recently, Li et al and Torabizadeh et al reported the labeling of peptide with HYNIC using the EDDA/tricine as coligands leading to preparation of radioconjugate with high stability, high radiochemical purity as well as tumor targeting. [11] Overall, 99m Tc-HYNIC-(EDDA/tricine)-(Ser) 3 -J18 showed higher NSCLC targeting as compared with the previously reported 99m Tc-EDDA/tricine-(Ser) 3 -D4 peptide, [21] because later radioconjugate showed low tumor-to-muscle and tumor-to-blood ratios that were 1.6 and 1.3 at 4 hr p.i., respectively, in the same xenografted animal model and coligands system. In the present study, three amino acid residues of serine were chosen as pharmacokinetic modifying linker.…”
Section: Discussionmentioning
confidence: 66%
See 3 more Smart Citations